Hepatitis Vaccine Uptake: Trends, Challenges, and the Role of Pharmacists

By João L. Carapinha

May 22, 2025

The recent podcast and article “The Common Trends in Hepatitis Vaccine Uptake, Hesitancy” highlights the urgent need to boost hepatitis vaccine uptake across age groups. Jeff Goad, PharmD, MPH, president of the National Foundation for Infectious Diseases, notes that both children and adults would benefit from higher vaccination rates. He suggests pharmacists can play a key role by offering vaccines during pharmacy visits to remove access barriers.

Disparities in Vaccination Rates

A key takeaway is the disparity in hepatitis vaccine uptake between children and adults. While hepatitis B vaccination rates for children exceed 90%, adult coverage remains alarmingly low. Hepatitis A vaccination rates are around 10%, and hepatitis B rates are below 50%. This gap presents a public health opportunity, as more than half of new hepatitis A and acute hepatitis B infections in 2018 occurred in individuals aged 30-49. Many were born before infant vaccination was advised.

Barriers to Vaccination

During the podcast, Goad identifies vaccine hesitancy fueled by misinformation as a major barrier. He distinguishes between: i ) misinformation – erroneous information spread unintentionally by unreliable sources, and ii) disinformation – deliberately misleading information disseminated to confuse the public. Common misconceptions include:

  • Hepatitis A only threatens travelers
  • Hepatitis A poses minimal risk for serious complications
  • Claims of harmful additives like mercury in vaccines
  • The false idea that hepatitis B vaccines are only for high-risk groups

Studies show various factors contribute to hesitancy, including vaccine unavailability (51.1%), personal hesitancy (18.8%), time constraints (18.4%), and financial barriers (11.7%).

The Pharmacist’s Role

Pharmacists can strengthen hepatitis vaccine uptake. As frequent patient interactors, they can:

  1. Administer vaccines during pharmacy visits
  2. Expand access with longer hours and walk-in options
  3. Provide accurate information to dispel myths
  4. Roll out mobile clinics for marginalized populations

Health Economics and Policy Implications

Untreated hepatitis B and C infections lead to high healthcare costs from chronic liver diseases, cirrhosis, and cancer. Preventive vaccination is cost-effective compared to managing these complications. Implementing adult vaccinations in at-risk settings—like homeless services, HIV clinics, and substance use programs—could improve uptake and optimize resources.

Pharmacies can expand vaccination services as both a public health opportunity and business strategy. Benefits include: i) diversifying income beyond dispensing, ii) boosting customer loyalty and foot traffic, iii) strengthening their role in preventive healthcare. Challenges like reimbursement, staffing, and workflow must be addressed.

Policy and Future Directions

A policy shift advocates universal hepatitis B vaccinations up to age 59, similar to flu shots. This requires reliable vaccine supply, provider education, public awareness campaigns, and unimpeded insurance coverage. Preventive measures like hepatitis vaccination will gain recognition for reducing long-term healthcare costs.

In conclusion, boosting hepatitis vaccine uptake needs collaboration among providers, public health groups, and policymakers. Pharmacists, with their accessibility and trust, can help close the vaccination gap. Explore the podcast and article further here.

Reference url

Recent Posts

HIV vaccine trials
    

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

🌍 Are we finally making strides in the fight against HIV?

Recent phase 1 vaccine trials using mRNA technology have shown promising results in activating immune responses that could lead to broadly neutralizing antibodies (bnAbs). This innovative approach not only addresses HIV’s rapid mutation but also offers critical insights for high-prevalence regions.

Dive into the full article to explore how these trials could shape the future of HIV prevention and what it means for global health!

#SyenzaNews #globalhealth #HIV #clinicaltrials

EHK clusters 2026 report
       

EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Cost Pharmaceuticals

🚀 Are you curious about how the Dutch healthcare system is adapting to high-cost pharmaceuticals?

The latest EHK clusters report for 2026 brings crucial updates to the risk-equalization model, enhancing equity among health insurers while closely managing skyrocketing costs. With innovative clustering techniques and revised reimbursement figures, these changes aim to improve access and accountability in an increasingly competitive healthcare landscape.

Dive into the full article to uncover the implications for health economics and policy!

#SyenzaNews #HealthEconomics #HealthcareInnovation

telemedicine growth strategies
          

Telemedicine Growth Strategies: Insights from the WHO European Region

🚀 Is telemedicine the future of healthcare as we know it?

The WHO’s latest policy brief reveals that while a remarkable 78% of Member States are integrating telemedicine into their national strategies, many face significant barriers to sustainable implementation. From regulatory inconsistencies to uneven infrastructure, understanding these challenges is key for effective long-term integration.

Dive into the insights and discover how we can harness telemedicine for equitable, quality care across the European Region.

#SyenzaNews #DigitalHealth #HealthcarePolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.